EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery
EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery

Average (ratings)
No ratings
 
  Your rating

In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.

SGLT2 inhibitors are proving to be the blockbuster drug of this decade: Sukh summarises and compares the learnings from DAPA-HF, Emperor-Reduced, and Emperor-Preserved. Next, Sukh highlights the data from SOLOIST-WHF that showed sotagliflozin to have beneficial effects on CV outcomes among patients with type 2 diabetes and HF. Additionally, they discuss how findings on finerenone (FIGARO-DKD) will shape the field. Sukh talks about the semaglutide and the STEP studies, an injectable medication that further expends cardiologist knowledge beyond their speciality. Ankur and Sukh reflect on how the advancement of this field shaped their own practices.

2021 was a busy year for cardiac surgery trials: Sukh and Ankur review the most pertinent data from the AVATAR randomised study presented at AHA 2021. Sukh interprets the outcomes and asks Ankur about his clinical experiences. Finally, they review the investigator led LAAOS III study that showed patients with atrial fibrillation undergoing cardiac surgery, left atrial appendage occlusion was superior to no occlusion.

What were the top practice informing heart failure trials of 2021? What does the latest data say on current cardiac surgery practices? How will these findings inform patient care?

Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.


Read MoreRead Less
Share
Edwards: www.edwardstavr.com

Brought to you by Edwards: www.edwardstavr.com

Read MoreRead Less
Up Next
EP 62: Bullying, Harassment and Jealousy at Workplace with Dr Srihari S Naidu
EP62 • Jan 31, 2022 • 43m 38s
In this week's Parallax, Dr Ankur Kalra is joined by Dr Srihari S Naidu, Director of Cath Labs and Hypertrophic Cardiomyopathy Center at the Westchester Medical Center and President Elect of NY ACC, for an honest conversation on a challenging topic within the cardiology community.
Read More
All Episodes
01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger
EP01 • Apr 23, 2020 • 27m 44s
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Parallax HFSA Edition: Diversity, Equity, Inclusion & Belonging with Dr Nancy M. Albert
EP56 • Oct 11, 2021 • 44m 26s
This week’s Parallax in collaboration with the Heart Failure Society of America (HFSA) explores the many ways organisations can embrace the needs of a diverse community and create a culture that can react to the realities of patientcare.
Read More
EP 55: 5 Interventional trials that will change your practice: Review of ESC 21 with Dr Mirvat Alasnag
EP55 • Sep 28, 2021 • 53m 38s
In the second ESC 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year’s ESC and regional PI of one of the late-breaking trials presented.
Read More
EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani
EP54 • Sep 06, 2021 • 1h
In this special ESC 2021 edition of Parallax, Ankur asks Purvi to review the highlights of the congress. Purvi summarises the design and findings of the trials and their importance in the treatment of patients. Ankur and Purvi discuss how the novel data presented at ESC will inform their practice.
Read More
EP 53: Belonging, Sparkplug & Purpose with Dr. Nasrien E. Ibrahim
EP53 • Aug 23, 2021 • 52m 54s
Dr Ankur Kalra’s guest is Dr Nasrien Ezzeldin Ibrahim, Director of Heart Failure Clinical Research at Inova Heart and Vascular Institute and the writer of SPARKPLUG: The Roadmap to Confidently Ignite and Navigate Your Career Without Compromising Your Dreams.
In this candid episode of Parallax, Nasrien and Ankur open up about their experiences of being an immigrant. Ankur asks Nasrien about her journey to medicine. Nasrien shares the lessons she took away from her years under the mentorship of Dr JoAnn Lindenfeld and later, Dr. James Januzzi. Finally, Nasrien shares her recent experience of writing Sparkplug and how she embraced life with its imperfections and found her purpose.
Read More
Parallax HFSA Edition: Diversity, Equity, Inclusion & Belonging with Robert Mentz & Anuradha Lala
EP52 • Jul 19, 2021 • 53m 54s
This week’s episode starts a series in collaboration with the Heart Failure Society of America (HFSA). Host, Ankur Kalra’s guests are Robert Mentz and Anuradha Lala Senior Editorial Team of the Journal of Cardiac Failure (JCF), the official journal of the HFSA and the Japanese Heart Failure Society (JHFS).
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
Read More